Table 2.
Response and status at 3 months after start of therapy and overall responses
| Response/status | Leiomyosarcoma (n = 10) | Malignant peripheral nerve sheath tumor (n = 6) | Synovial sarcoma (n = 4) | Undifferentiated pleomorphic sarcoma (n = 4) | Osteosarcoma (n = 4) | Othersa (n = 9) | Total (n = 37) |
|---|---|---|---|---|---|---|---|
| Best overall response | |||||||
| Partial response | 0 | 2 | 1 | 1 | 0 | 1 | 5 |
| Stable disease | 6 | 2 | 2 | 1 | 0 | 6 | 17 |
| Progressive disease | 4 | 2 | 1 | 2 | 2 | 1 | 12 |
| Early death (progressive disease) | 0 | 0 | 0 | 0 | 2 | 1 | 3 |
| Response at 3 months | |||||||
| Partial response | 0 | 2 | 1 | 1 | 0 | 0 | 4 |
| Stable disease | 3 | 2 | 2 | 1 | 0 | 5 | 13 |
| Progressive disease | 6 | 2 | 1 | 1 | 1 | 3 | 14 |
| Early death (progressive disease) | 1 | 0 | 0 | 1 | 3 | 1 | 6 |
| Number of patients progression free at 3 months | 3 | 4 | 3 | 2 | 0 | 5 | 17 |
| Proportion of patients progression free at 3 months, % | 30.0 | 66.7 | 75.0 | 50.0 | 0 | 55.5 | 45.9 |
a
Others: angiosarcoma (n = 4), liposarcoma (n = 1), alveolar soft part sarcoma (n = 1), myxofibrosarcoma (n = 1), hemangiopericytoma (n = 1), and rhabdomyosarcoma (n = 1).